Guardant Health: Roberto Mignone
Guardant Health has appointed Roberto Mignone to its board of directors, effective immediately. Mignone is the founder and managing partner of Bridger Management, an investment firm specializing in long-term equity strategies. Prior to Bridger Management, Mignone cofounded Blue Ridge Capital. He currently serves as the co-vice chairman at New York University's Langone Medical Center. He is also a member of the board at Teva Pharmaceuticals.
SpeeDx: Jeremy Stackawitz, Colin Denver
SpeeDx has named Jeremy Stackawitz as its CEO, replacing Colin Denver. Stackawitz most recently served as CEO of Senzo Health, and previously held positions at AliveDx (formerly known as Quotient), McKinsey & Company, and Johnson & Johnson. He will focus on accelerating SpeeDx's commercialization, partnering, and regulatory activities across key markets, including the US.
US Food and Drug Administration: Michelle Tarver
The US Food and Drug Administration has named Michelle Tarver the new permanent director of its Center for Devices and Radiological Health (CDRH), replacing former CDRH head Jeff Shuren.
Tarver was previously CDRH deputy center director and deputy director of the Office of Strategic Partnerships and Technology Innovation. Prior to that she was a medical officer in CDRH's Office of Surveillance and Biometrics, Division of Epidemiology. She began her FDA career as a staff fellow.
MedGenome: Felix Olale, Jennifer Rose, Amit Kakar
Felix Olale has been appointed as president and CEO and Jennifer Rose as executive VP and chief commercial officer of MedGenome.
Olale, previously chairman of MedGenome's board of directors, was most recently global co-lead of healthcare investments at LeapFrog Investments. Amit Kakar, managing partner and head of Novo Holdings Asia, will succeed him as chairman of MedGenome.
Rose was previously regional VP of business development at Precision for Medicine. She also held senior leadership roles at NeoGenomics Laboratories, GE Healthcare, PerkinElmer, and Thomson Reuters. She holds a master's degree in chemical engineering from the University of Connecticut and a bachelor's degree from Clemson University.
DNAnexus: Nupura Kolwalkar, Bill Madigan
Nupura Kolwalkar has been appointed as chief product officer and Bill Madigan as chief commercial officer of DNAnexus.
Kolwalkar previously held executive positions at McKesson, Brightree, ResMed, Datavant, Sharecare, NextGen Healthcare Information Systems, and Pfizer. She holds an M.S. in computer science from Auburn University and an M.A. in industrial statistics and econometrics from Savitribai Phule Pune University in India.
Madigan was previously chief revenue officer at Komodo Health. Before that, he held leadership roles at Optum's healthcare and life sciences business units including senior director for Optum Life Sciences and head of provider analytics. He holds a master's degree in business, technology, and finance from the D'Amore-McKim School of Business at Northeastern University.
For additional recent items on executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.